Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 0.61 |
| ▸ | F3 | P13726 | 20/20 | 0.61 |
| ▸ | F10 | P00742 | 16/20 | 0.61 |
| ▸ | F2 | P00734 | 15/20 | 0.61 |
| ▸ | F11 | P03951 | 13/20 | 0.61 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538029 | 0.95 | F7 (0.66) | F7F3F10F2F11 | |
| Trifluoroacetic Acid SCHEMBL2543795 | 0.91 | F7 (0.74) | F7F3F10F2F11 | |
| Trifluoroacetic Acid SCHEMBL2540634 | 0.90 | F7 (0.56) | F7F3F10F2F11 | |
| Trifluoroacetic Acid SCHEMBL2852628 | 0.89 | F7 (0.75) | F7F3F10F2F11 | |
| Trifluoroacetic Acid SCHEMBL2850912 | 0.89 | F7 (0.75) | F7F3F10F2F11 | |
| Trifluoroacetic Acid SCHEMBL2543355 | 0.88 | F7 (0.51) | F7F3F10F2F11 | |
| SCHEMBL2537013 | 0.86 | F7 (0.81) | F7F3F10F2F11 | |
| Trifluoroacetic Acid SCHEMBL2539538 | 0.86 | F7 (0.48) | F7F3F10F2F11 | |
| SCHEMBL2542855 | 0.86 | F7 (0.59) | F7F3F10F2F11 | |
| SCHEMBL12249919 | 0.84 | F7 (0.51) | F7F3F10F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996541-B1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8044242-B2 | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F12 | F7 1/4885F3 11/4885F10 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.